05, SCLC compared with LSCC and LAC, respectively; ▴ p < 0.05, LSCC compared with LAC and SCLC, respectively; ★★ p<0.0005, N0 compared with N1, N2, and N3, respectively; ▴▴ p<0.0005, N0 compared with N1, N2, and N3, respectively; ● p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; ●● p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; SCLC, small cell lung cancer; LCLC, large cell lung cancer; Smoking, pack years of smoking. Figure 2 Correlation between clinico-pathological features and the expression of Hsp90-beta

and annexin A1 in lung cancer. (A and B) Upregulation of Hsp90-beta GANT61 supplier and annexin A1 was observed in poorly differentiated lung cancer tissues compared with well-differentiated tissues (p < 0.0005); (C and D) Hsp90-beta and annexin A1 expressions in lung cancer cases without lymphnode

metastasis was lower than that in lung cancer cases with lymph node metastasis (p < 0.0005); (E and F) Upregulated Hsp90-beta and annexin A1 was found in lung cancer tissues at stages III to IV compared with that at stages I to II (p = 0.002). Association between mRNA and protein expressions of Hsp90-beta and annexin A1 in the matched cancer tissues and adjacent normal tissues Twenty-four matched fresh cancer tissues and adjacent normal tissues were collected from November 2010 to October 2011. The tissues were protected according to the standard Cisplatin concentration process to prevent mRNA degradation. The mRNA expression levels of Hsp90-beta and annexin A1 were determined using ISH in these fresh sections. High mRNA expression levels of Hsp90-beta and annexin A1 were observed Diflunisal in ten (41.7%) and eight (33.3%) of the 24 lung cancer tissues, whereas both markers were lowly expressed in two (8.3%) and three (12.5%) of the 24 normal lung tissues, respectively. An upregulated mRNA expression of Hsp90-beta and annexin A1 was found

in the lung cancer tissues (p = 0.006; p = 0.002) (Table 5, Figures 3 A, B, C, D, E, F, G, H, I, J, K, and L). The mRNA expressions of Hsp90-beta and annexin A1 were consistent with protein expression (McNemar test, p > 0.05). We performed Western blot to VX-770 concentration confirm the differential expressions of Hsp90-beta and annexin A1 and to verify their differential expressions in the matched cancer tissues and adjacent normal tissues. Equal protein loading was indicated by a parallel β-actin blot experiment. As shown in Figure 4, Hsp90-beta and annexin A1 were upregulated in cancerous tissues compared with normal tissues (p < 0.05) (Figure 4). Table 5 The mRNA and protein expressions of Hsp90-beta and annexin A1 in matched cancer tissues and adjacent normal tissues Groups   N Expression of Hsp90-beta Expression of annexin A1 Low (%) Moderate (%) High (%) χ 2value pvalue Low (%) Moderate (%) High (%) χ 2value pvalue mRNA                           Normal 24 13(54.2) 9(37.5) 2(8.3) 10.15 0.006 15(62.5) 6(25) 3(12.5) 12.85 0.002   Cancerous 24 4(16.7) 10(41.